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WAP four-disulfide core domain protein 2
gene(WFDC2) is a target of estrogen in
ovarian cancer cells
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Abstract
Background: WAP four-disulfide core domain protein 2 (WFDC2) shows a tumor-restricted upregulated pattern of
expression in ovarian cancer.
Methods: We investigated the role of estradiol (E2) on cell growth in estrogen-sensitive or estrogen-insensitive
ovarian cancer cell lines. Real-time (RT)-PCR and western blotting were used to examine the expression of WFDC2
at RNA and protein levels. Growth traits of cells transfected with WFDC2-shRNA or blank control were assessed
using MMT arrays. Cell apoptosis was analyzed using annexin V-FITC/PI and flow cytometry. Estrogen receptor
expression was evaluated using RT-PCR and flow cytometry. Apoptosis-related proteins induced by E2 directly and
indirectly were determined using an antibody array comparing cells transfected with WFDC2- shRNA or a blank
control.
Results: High-dose (625 ng/ml) E2 increased the expression of WFDC2 in HO8910 cells at both the mRNA and
protein levels. However, E2 had no effect on WFDC2 expression in estrogen-insensitive SKOV3 cells. Of interest,
knockdown of WFDC2 enabled a considerable estrogen response in SKOV3 cells in terms of proliferation, similar to
estrogen-responsive HO8910 cells. This transformation of SKOV3 cells into an estrogen-responsive phenotype was
accompanied by upregulation of estrogen receptor beta (ERß) and an effect on cell apoptosis under E2 treatment
by regulating genes related to cell proliferation and apoptosis.
Conclusions: We postulate that increased WFDC2 expression plays an important role in altering the estrogen
pathway in ovarian cancer, and the identification of WFDC2 as a new player in endocrine-related cancer encourages
further studies on the significance of this gene in cancer development and therapy.
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Background
Ovarian cancer is one of the most common cancers
among women and the leading cause of death from
gynecological malignancies in the world [1, 2]. The
underlying causes of ovarian cancer are poorly under-
stood and largely untested, but estrogen, as a major ster-
oidal product of the ovary, has been shown to be
associated with increased ovarian cancer risk in estrogen
receptor (ER)-expressing cells [3–5]. Hormone replace-
ment therapy (HRT) has been widely used in women
with estrogen-withdrawal syndromes. Estrogen has been
associated with an increased ovarian cancer risk and it
can promote tumor growth and cell proliferation in ER-
expressing cell lines. The main biological functions of
estrogen are manifested through transcriptional activa-
tion of the ligand-dependent ERs, ERα and ERβ [3, 6].
More than two-thirds of ovarian cancer patients are
positive for ERα [6–8]. The activation of ER results in an
altered expression of its direct transcriptional targets,
thereby affecting a series of downstream secondary bio-
logical activities. However, the regulatory effects of es-
trogen on the behavior of ovarian tumor cells involves a
complex signaling network and the underlying mecha-
nisms are still not fully understood. Therefore,
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identification of novel targets regulated by estrogen
will be very important to clarify the specific impact of
estrogen on ovarian tumor growth and facilitate the
development of new diagnostic and therapeutic
markers [4, 5, 9].
In recent years, a number of studies have shown that
numerous estrogen-responsive genes, including insulin-
like growth factor binding protein (IGFBP) family mem-
bers (IGFBP3, IGFBP4 and IGFBP5), trefoil factor (TFF)
family members (TFF1 and TFF3), and TNF receptor-
associated protein 1 (TRAP1) among others, affect the
growth and development of ovarian cancer [10, 11].
Genomic analysis of ovarian cancer identified gene amp-
lification of the WFDC2 gene (that encodes the human
epididymis protein 4 (HE4)) and the whey acidic protein
gene loci in a large proportion of epithelial ovarian can-
cers [12, 13]. HE4 exhibits a tumor-restricted, upregu-
lated pattern of expression in ovarian cancer, making it a
potential marker [12, 14, 15]. The previous work has
shown a direct linkage between HE4 expression and cell
proliferation; however the molecular mechanisms are
still unclear [12, 16]. To date, the majority of studies
have focused on the potential value of HE4 as a diagnos-
tic using various serologic tests, but very little attention
has been paid to the role of HE4 in tumor development
of ovarian cancer [12, 14, 17].
The WFDC2 gene is located on human chromosome
20q12-13.1, a region that includes 14 genes that encode
proteins with a WAP-type four-disulfide core (WFDC)
domain [14, 17]. Two of the best-studied members of
the WAP gene family are SLPI and PI3 (that encodes for
elafin), both having antiproteinase activity. They are co-
expressed with WFDC2 and involved in cancer develop-
ment or progression in various carcinomas affected by
sex hormones [9, 14, 18]. So we could not help to specu-
late that WFDC2 might also play some role in the
estrogen-sensitive ovarian cancers.
As a cancer-specific gene, several hormone-response
elements were found within the WFDC2 promoter, in-
cluding an estrogen response element (ERE) and RORA,
which may be attributed to HE4 upregulation in ovarian
cancer and ovarian cancer specificity [19]. The amount
of HE4 in blood samples was significantly different be-
tween follicular (FP) and ovulatory (OP) phases of the
hormonal cycle, being lower in the FP than in the OP
[20]. The menstrual cycle phase-dependent variability in-
dicated that WFDC2 expression might be affected by the
menstrual cycle of women. These results suggested that
WFDC2 might be an estrogen response gene, and play
important roles in the cell proliferation and malignant
transformation of ovarian cancer.
In this study, we investigated the regulatory effects of
estrogen and estrogen antagonist on WFDC2 gene ex-
pression in estrogen sensitive HO8910 cells and estrogen
insensitive SKOV3 cells, with the aim to determine
whether WFDC2 is an estrogen-responsive gene. And
then, we transfected these cells with short hairpin RNA
(shRNA) against WFDC2, and investigated the effect of
WFDC2 silencing on cell proliferation, its interaction
with ER and its effect on ER-mediated signaling.
Methods
Cells and treatments
The cell bank of the Chinese Academy of Sciences
(Shanghai, China) supplied the human ovarian cancer
cell lines, HO8910 and SKOV3 (American Type Culture
Collection (ATCC), Manassas, VA, USA). Cells were
maintained in minimal essential medium supplemented
with 10 % (v/v) fetal bovine serum (FBS) at 37 °C in an
atmosphere of 95 % air, 5 % CO2. The ligand 17β-
estradiol (E2) and the selective ER modulator (SERM),
tamoxifen (TAM), were purchased from Sigma-Aldrich
(St Louis, MO, USA). Before the cells were treated with
the ligands, the medium was replaced with minimal es-
sential medium supplemented with 0.5 % FBS. Cells
were treated with different concentrations of E2 (5, 25,
125, 625 and 1250 ng/ml), and TAM (100 ng/ml), for
24 h prior to quantitative real-time PCR (QPCR) and
48 h prior to western blotting and protein array analysis.
RNA extraction and QPCR
Total RNA was isolated following the manufacturer’s in-
structions (PrimeScript 1st Strand cDNA Synthesis Kit,
TAKARA). Reverse transcription was also performed
following the manufacturer’s instructions in a total vol-
ume of 20 μl using an oligo-dT primer and 1 μg of total
RNA. Each primer set was designed using Primer Ex-
press software v3.0 to flank an intron to prevent the
amplification of genomic DNA. β-actin was used to
evaluate the efficiency and variability of the reverse tran-
scription step. CDNA samples (0.1 μg) were amplified
using the SYBR Green PCR Master Mix (TAKARA)
under conditions recommended by the manufacturer: (a)
pre-incubation at 95 °C for 30 s; (b) 40 PCR cycles of
95 °C for 5 s, 55 °C for 30 s, and 72 °C for 34 s. Samples
were assayed in duplicate using the ABI Prism 7500 de-
tection system (Perkin Elmer Applied Biosystems). The
relative quantification number was then calculated by
subtracting the average CT from the corresponding aver-
age CT for β-actin.
Western blotting
Total protein was extracted using sonication in radio-
immunoprecipitation assay (RIPA) buffer (50 mM Tris–
HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5 % Nonidet
P-40, 5 mM dithiothreitol, 10 mM NaF, and protease in-
hibitor cocktail). One hundred micrograms of denatured
protein was separated on an SDS-polyacrylamide gel and
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transferred to a Hybond membrane (Amersham,
Germany), which was then blocked overnight in 5 %
skim milk in Tris-buffered saline with Tween 20 (TTBS,
10 mM Tris–HCl, 150 mM NaCl, 0.1 % Tween 20). For
immunoblotting, the membrane was incubated for
15 min with the WFDC2 antibody. The membrane was
rinsed with TTBS and incubated with anti-rabbit IgG
conjugated to horseradish peroxidase (DAKO, USA,
1:1000) for 15 min. All incubations were performed in a
microwave oven to allow intermittent irradiation. Bands
were visualized on an ImageQuant LAS4010 (GE
Healthcare Life Science, USA) using ECL-Plus detection
reagents (Santa Cruz, USA). Densitometric quantifica-
tion of protein bands with GAPDH as an internal con-
trol was performed using Image J (NIH, USA).
Gene silencing
The WFDC2-specific shRNA sequence (5′-GCTCT
CTGCCCAATGATAAGG-3′) (based on the Gene Bank
Accession No. NM_0006103.3) and its control sequence
(5′-GTTCTCCGAACGTGTCACGT-3′) were chem-
ically synthesized and cloned into the pGLV-U6-GFP
vector by Shanghai GenePharma Co. Ltd (Camsonne
et al.). Lentiviruses, purchased from the same company,
were transduced into the HO8910 cell line according to
the manufacturer’s instructions. For stable silencing of
WFDC2, the transduced HO8910 cell line, named
HO8910-209, was selected using puromycin. Puromycin-
resistant colonies were then picked, expanded and ana-
lyzed separately.
Cell proliferation assays
The in vitro proliferation assay was performed using the
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay following the manufacturer’s in-
structions (Sigma). Briefly, 500 cells per well were plated
in 96-well plates in triplicate. After a 24 h incubation,
cells were serum-starved for 24 h and then treated with
different concentrations of estrogen (0, 5, 25, 125, 625
and 1250 ng/ml) or TAM for 6 days. At the indicated
time, cell proliferation was determined by measurement
of the absorbance values using the MTT assay method,
and cell growth curves were then plotted.
Flow cytometry
Cells were trypsinized and washed three times with
phosphate-buffered saline (PBS). Cells were then
digested with 1 % RNase at 37 °C for 30 min and stained
with annexin V-FITC for 30 min, followed by staining
with propidium iodide (PI, Sigma, Shanghai, China) for
5 min at 4 °C for cell apoptotic analysis. The results were
analyzed using WinMDI software with 10,000 events
collected for each sample. Cell suspensions were also in-
cubated with antibodies to ERα and ERß (1 μg/1 × 106
cells) for 30 min at 37 °C. Cells were then washed three
times with PBS, and incubated with PE and an FITC-
labeled secondary antibody for 30 min at 37 °C. Cell sus-
pensions were washed three times with PBS. Expression
of ERα and ERß per 10000 cells was determined using
flow cytometry.
Annexin V-FITC/PI staining
Apoptosis was evaluated using the Annexin V-FITC/PI
Apoptosis Detection kit (BestBio, Shanghai, China) using
fluorescence microscopy according to the manufacturer’s
instructions. Briefly, cells were grown onto a cover slide
and incubated with E2 (625 ng/ml) for 24 h. The adher-
ent cells were washed twice with ice-cold PBS and
stained with annexin V-FITC and PI for 15 min and ex-
amined under a light microscope equipped with appro-
priate filters. Apoptotic cells stained with annexin V-
FITC showed green fluorescence, and necrotic cells
stained with both annexin V-FITC and PI produced red
fluorescence as well as green fluorescence.
Human antibody array for apoptotic-related proteins
Apoptotic-related proteins induced by E2 directly and
indirectly were determined using the RayBio® Label-
Based Human Antibody Array kit (RayBio® Human
Apoptosis Antibody array) (RayBiotech, Norcross, GA).
Densitometric analysis was performed on a Kodak Ima-
geStation 4000 M (Eastman Kodak Company, Rochester,
NY) with background subtraction from spot edges fol-
lowing the manufacturer’s instructions. Spot data were
normalized to a positive control spot on each array.
Statistics
Microsoft Office Excel 2007 and the statistical software
SPSS13.0 were used in data processing and the t-test
was used in analyzing significance. P values < 0.05 were
considered statistically significant. Data were expressed
as the mean ± SD from at least three independent
experiments.
Results
High-dose E2 induces expression of WFDC2 in HO8910
cells
To determine if HE4/WFDC2 is a downstream target of
E2 signaling pathways, we induced the expression of the
WFDC2 gene by adding E2 into the culture of HO8910
cells using a range of concentrations (0, 5, 25, 125, 625
and 1250 ng/ml). The results indicated that the WFDC2
gene was upregulated only when cells were treated with
a high dose of E2. The expression of WFDC2 at both
mRNA and protein levels was increased with E2 from
125 to 1250 ng/ml as detected using QPCR (P < 0.05)
(Fig. 1a) and western blotting (P < 0.05) (Fig. 1b). At a
concentration of 625 ng/ml, E2 increased the protein
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level of WFDC2 by 2.54-fold. The effect of E2 on
WFDC2 expression was not dose-dependent (Fig. 1c).
After 24 h treatment, expression of WFDC2 was ob-
served to be upregulated and the upregulation was sus-
tained for over 48 h (Fig. 1c).
We next determined whether the ER signaling path-
way regulated WFDC2 mRNA expression. SKOV3 ovar-
ian carcinoma cells have functional ERs but are
insensitive to estrogen [21]. We used SKOV3 cells to
prove whether WFDC2 was induced by estrogen. A basal
level of WFDC2 was detected in SKOV3 cells but pro-
tein expression was not induced by E2 (data not shown).
HO8910 cells were incubated with TAM (100 ng/ml) for
8 h and then with E2 (0, 5, 25, 125, 625 and 1250 ng/ml)
for a further 36 h. Cells were then harvested and expres-
sion of WFDC2 analyzed. Amounts of WFDC2 were in-
creased by adding E2 to HO8910 cells and not affected
by adding TAM (Fig. 1d).
These results indicated that WFDC2 was a down-
stream target of E2 but that regulation might not be
through the ERα pathway.
Knockdown of WFDC2 expression reduces cell
proliferation driven by estrogen
The dependence of WFDC2 expression on estrogen ac-
tivity led us to study whether the proliferative growth of
ovarian cancer cells induced by E2 was mediated by
WFDC2. The sequence 209 shRNA, which was shown to
Fig. 1 E2 induces expression of WFDC2 in HO8910 cells. a Real-time RT-PCR analysis of the expression of WFDC2 and GAPDH in HO8910 cells after
stimulation with E2 at different concentrations for 48 h (n = 3). The relative amounts of WFDC2 protein were determined using densitometry and
normalized to GAPDH. *P <0.05. b Western blot analysis of the expression of WFDC2 and GAPDH in HO8910 cells after stimulation with E2 at
different concentrations for 48 h (n = 3). The relative amounts of WFDC2 protein were determined using densitometry and normalized to GAPDH.
*P < 0.05 versus the solvent control. c Western blot analysis of the expression of WFDC2 and GAPDH in HO8910 cells after stimulation with
625 ng/ml E2 at different time points. n = 3, *P < 0.05 versus 0 h. d Western blot analysis of the expression of WFDC2 and GAPDH in HO8910 cells
incubated with TAM (100 ng/ml) for 8 h and then incubated with E2 (625 ng/ml) for 36 h. n = 3, *P < 0.05 versus the control
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effectively knock down the expression of WFDC2 in
SKOV3 cells [12], was inserted into the retroviral vector
and transduced into estrogen-sensitive HO8910 cells to
produce the stable WFDC2 knockdown cell line
(HO8910-209) (Additional file 1: Figure S1). Therefore,
we compared the growth of HO8910-209 or SKOV3-209
cells with the negative control clone of each cell line to
determine the role of WFDC2 both in estrogen-sensitive
and estrogen-insensitive ovarian cancer cells.
Combined with previous results, knockdown of the ex-
pression of WFDC2 dramatically decreased the cell pro-
liferation of both HO8910-209 and SKOV3-209 cells
(Fig. 2a). Additionally, we performed growth assays with
high-dose E2 (625 ng/ml) to analyze the effect of
WFDC2 knockdown on E2-triggered proliferation.
Addition of E2 further decreased proliferation of
HO8910-209 cells and the relative estrogen response of
this cell line was not changed significantly by WFDC2
knockdown (Fig. 2b). In contrast, addition of high-dose
E2 had very little effect on cell proliferation of estrogen-
unresponsive SKOV3 cells, while the growth of SKOV3-
209 cells was inhibited significantly by high-dose E2
compared with the SKOV3-NA cells. These results indi-
cated that WFDC2 knockdown might transform the
estrogen-unresponsive SKOV3 cells from a hormone-
independent to an estrogen-responsive phenotype
(Fig. 2b). This transformation of ovarian cancer cells
from a hormone-independent to an estrogen-responsive
phenotype using knockdown of a single gene was further
validated in proliferation experiments combining E2
with the SERM, TAM [22].
In estrogen-sensitive HO8910 cells, treatment with
TAM resulted in the expected anti-proliferative effect on
this cell line, which was also enhanced by WFDC2
knockdown (Fig. 2c). Compared with HO8910 cells,
treatment with TAM (100 ng/ml) did not affect the
growth of SKOV3 cells significantly. While knockdown
of WFDC2 in this cell line enabled a strong inhibitory
effect of TAM on E2-triggered growth of ~65 % after
5 days of treatment (Fig. 2c), this drug did not signifi-
cantly affect the growth of negative control SKOV3 cells.
Thus, the results indicated that knockdown of WFDC2
not only increased the sensitivity of ovarian cancer cells
to the growth inhibition induced by high-dose E2, but
Fig. 2 Knockdown of WFDC2 expression reduces cell proliferation and enables an E2 response in SK-OV-3 ovarian cancer cells. HO8910 (a) or
SKOV-3 (b) cells were treated with or without E2 (625 ng/ml) and knockdown of WFDC2 reduced the viable cell number compared with the
negative control. n = 3 *P < 0.05; **P < 0.01. E2 response of HO8910 (c) and SKOV3 (d) cells. Knockdown of WFDC2 enabled an E2 response in
SK-OV-3 ovarian cancer cells. HO8910 (e) or SKOV-3 (f) cells were treated with E2 (625 ng/ml) alone or in combination with TAM (100 ng/ml), and
knockdown of WFDC2 increased the inhibition efficiency in ovarian cancer cells by adding TAM compared with the control; *P < 0.05, **P < 0.01
for TAM versus the control. ΔP < 0.05, verus cells treated with TAM without ShRNA interference
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also transformed the estrogen-unresponsive SKOV3 cells
from a hormone-independent to an estrogen-responsive
phenotype.
WFDC2 knockdown promotes apoptosis induced by high-
dose estrogen
Since E2 was shown to inhibit ovarian cancer cell
growth, we investigated whether high-dose hormone
treatment induced apoptosis in ovarian cancer cells. In
this study, we performed flow cytometry and annexin V-
FITC/PI staining to detect apoptosis of estrogen-
responsive HO8910 cells and estrogen-unresponsive
SKOV3 cells.
The influence on cell cycle of high-dose estrogen was
limited, while cell apoptosis was significantly increased
by E2 in both WFDC2-knockdown cells and the control
group, particularly in WFDC2-knockdown cells (Fig. 3a).
As shown in Fig. 3c, the percentage of apoptotic
HO8910-209 cells [21.6 % (±6.24)] was significantly
higher than that of HO8910-NA cells [12.4 % (±4.28)]
when treated with E2 (p < 0.05). The same results were
observed with SKOV3 cells (Fig. 3c). The percentage of
apoptotic SKOV3-209 cells [16.2 % (±7.2)] was signifi-
cantly higher than that of SKOV3-NA cells [9.6 %
(±5.68)] when treated with E2 (p < 0.05). Thus, knock-
down of WFDC2 expression in ovarian cancer cells in-
creased cell apoptosis induced by high-dose E2 in both
estrogen-sensitive and estrogen-insensitive cells.
Knockdown of WFDC2 decreases expression of ERβ in
HO8910 and SKOV3 cells
Given that WFDC2 knockdown transformed a hormone-
unresponsive ovarian cancer cell line in an estrogen-
responsive one, we were eager to know how this would
be reflected at the gene expression level. For this pur-
pose, we studied expression of ERα and ERβ.
As shown in Fig. 4a, knockdown of WFDC2 expres-
sion led to no change in the level of ERα mRNA in ei-
ther HO8910 or SKOV3 cells. In contrast, expression of
ERβ was strongly increased in both cell lines.
We then used flow cytometry to determine whether
upregulation of ERβ expression occurred at the protein
level. HO8910 cells exhibited very weak ERβ protein ex-
pression but both HO8910 and SKOV3 cells showed
Fig. 3 Knockdown of WFDC2 increases cell apoptosis induced by estrogen. a The fraction of apoptotic cells detected using flow cytometry. b
Apoptotic activity of 625 ng/ml E2 in WFDC2 knockdown cells and control cells detected using Annex V-FITC/PI staining. c Quantification of the
percentages of apoptotic cells in WFDC2 knockdown cells and control cells treated with 625 ng/ml E2. *P < 0.05 compared with the control
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Fig. 4 Knockdown of WFDC2 increases expression of ERß in HO8910 and SK-OV-3 cells. a Normalized ERα and ERß RNA levels in WFDC2 knockdown
cells and control cells using real-time RT-PCR. The relative quantities of ERα and ERß were determined using densitometry and normalized with GAPDH.
*P < 0.05 versus the control. b Flow cytometric graphs for ERß expression in WFDC2 knockdown cells and control cells. c Quantification of the
percentages of ERß-positive cells in WFDC2 knockdown cells and control cells. *P < 0.05 versus the control
Fig. 5 Genes related to cell apoptosis induced by E2 were modified by WFDC2 knockdown. a Original figure of RayBio® Human Apoptosis
Antibody array. b Graph of gene expression detected using the Human Apoptosis Antibody array. *P < 0.05 compared with the control
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upregulation of ERβ expression in WFDC2-knockdown
cell lines. The percentage of positive cells with ERβ ex-
pression was higher in WFDC2-knockdown cells than in
the negative control cells (Fig. 4b).
WFDC2 regulates genes related to cell apoptosis under
estrogen treatment
To explore the molecular mechanisms, RayBio® Human
Apoptosis Antibody array was used to screen protein ex-
pression of a range of apoptosis-related genes (Fig. 5a).
Figure 5b shows the protein microarray signal intensities
for apoptotic-related genes in HO8910-NA and HO8910-
209 cells. Notably, the microarray intensities of HSP27,
IGF-1, IGFBP, P21, HTRA, survivin and XIA were more
highly suppressed in HO8910-209 than in HO8910-NC
cells.
In hormone-unresponsive SKOV3 cells, we observed
that the microarray protein intensities of Bad (Bcl-2 an-
tagonist of cell death), Bax (Bcl-2 associated X protein),
Bim (Bcl-2 interacting mediator), caspase 3, caspase 8
and Fasl were higher, and the microarray intensities of
P21 and Hsp60 were lower. Though the genes affected
by WFDC2 knockdown were not identical in estrogen-
sensitive HO8910 and estrogen-insensitive SKOV3 cells,
using these data, we hypothesized that WFDC2 might
represent a mechanism by which estrogen signaling in-
duced cell apoptosis.
Discussion
Estrogen plays a crucial role in the control of develop-
ment, sexual behavior and reproductive functions. Its ef-
fects have been linked to the progression of the majority
of human ovarian cancers and acts as a potent mitogen
for many ovarian cancer cell lines [3, 23]. In this study,
we undertook to prove the hypothesis that WFDC2 is
regulated by estrogen and that it might play a role in
tumorigenesis induced by estrogen in ovarian cancer.
In this study, we demonstrated that high-dose E2 in-
duced the upregulation of WFDC2 gene expression in
estrogen-sensitive HO8910 cells, while no induction ef-
fect was observed in estrogen-insensitive SKOV3 cells.
However, the estrogen selective inhibitor TAM could
not block estrogen-induced WFDC2 expression. These
results provide evidence of a positive relationship be-
tween WFDC2 expression and estrogen action; however,
the regulatory effect might not be through the ERα path-
way only, which will require further experiments to
prove definitively.
This study also provides the first evidence for a func-
tional role of the WFDC2 gene in the estrogen-
dependent proliferation of ovarian cancer cells. It is gen-
erally considered that the proliferative effects of estrogen
in cell culture occur at picomolar or nanomolar concen-
trations, typical levels in serum [1]. However, the ovary
is an estrogen secretion organ, and thus micromolar
concentrations of estrogen occur within the ovary and
play a role in cell biology or transformation of normal
ovarian surface epithelium and ovarian cancer cells,
which has been largely overlooked [24, 25]. Proliferation
in response to physiological concentrations of E2 has
been reported in cultured ovarian cancer cells expressing
ER, but currently there is no direct evidence in support
of the hypothesis that high E2 levels present within the
microenvironment of the ovary following ovulation con-
tribute to the induction of ovarian cancer. Although
physiological concentrations of estrogen can stimulate
breast cancer cell proliferation, high-dose estrogens
cause regression of some ER-positive human breast
tumors.
In this study, we observed significant inhibition of cell
growth induced by high-dose estrogen in estrogen-
sensitive HO8910 cells, and a slight inhibition of cell
growth in estrogen-insensitive SKOV3 cells. The sup-
pression of the endogenous WFDC2 in ovarian cancer
cells not only inhibited cell growth, but also significantly
strengthened the response of estrogen-insensitive
SKOV3 cells to estrogen. These data suggest the involve-
ment of WFDC2 in estrogen signaling and in estrogen-
responsiveness of ovarian cancer cells. We also found
that WFDC2 knockdown could affect the hormone-
dependent proliferation not only in HO8910-sensitive
but also in SKOV3-insensitive cells. WFDC2 knockdown
decreased proliferation of SKOV3 ovarian cancer cells
and, more strikingly, switched on a strong estrogen re-
sponse in this estrogen-unresponsive cell line.
This transformation of ovarian cancer cells from
hormone-independent to an estrogen-responsive pheno-
type by knockdown of a single gene was further vali-
dated in proliferation experiments combining E2 with
TAM. As shown in the results, WFDC2-knockdown in-
creased the sensitivity of cells to TAM not only in
estrogen-sensitive, but also in estrogen-insensitive cells.
The suppression of the endogenous WFDC2 in ovarian
cancer cells was more likely suppressed by TAM. Thus,
the specific role of WFDC2 in cell growth in the micro-
environment with high-dose estrogen may be associated
with ovarian epithelial cancer cell growth and transform-
ation, and may also be involved in TAM resistance.
Previously, we demonstrated that the expression of
WFDC2 promoted cell proliferation as well as G1/S
transition, while stimulating cyclin D1 expression [12].
Cyclin D1 has been confirmed as one of the estrogen
target genes, and confers the mitogenic role of estrogen
[26]. These results led us to postulate that WFDC2 par-
ticipated in estrogen-dependent proliferation through
regulating expression of cell cycle checkpoint proteins.
While, no previous evidence has been presented,
WFDC2 has been shown to be associated with cell
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apoptosis [12]. We further analyzed whether apoptosis,
regulated by estrogen, could be affected by WFDC2 ex-
pression. Using FACS analysis, we showed that high con-
centrations of estrogen could significantly increase the
level of cell apoptosis, and that loss of WFDC2 expres-
sion resulted in a significant increase in the rate of apop-
tosis under high-dose estrogen both in estrogen-
sensitive and insensitive cells. Our results demonstrated
that pharmacological concentrations of estrogen induced
apoptosis in human ovarian cancer cells that involved
WFDC2 expression.
ER has been considered to be an important regulator
of estrogen-sensitive cell behavior. The response of neu-
rons to estrogen depends on the ER subtype expressed
in the cell. ERα is known to stimulate proliferation in re-
sponse to estrogens by increasing expression of genes
connected with cell cycle progression like cyclin D1 or
growth factors, and by downregulating antiproliferative
and proapoptotic genes [26, 27]. Lokich et al. demon-
strated that WFDC2 interacted with ERα, and that
WFDC2 overexpression resulted in ERα downregulation
in ovarian cancer cells [19]. In our study, we did not ob-
serve upregulation of ERα in HO8910-209 cells; indeed,
expression of ERα was almost unchanged by WFDC2
knockdown. While WFDC2 knockdown resulted in up-
regulation of ERβ in both HO8910 and SKOV3 cells.
ERβ has been described to act as an antagonist of ERα
in certain settings and to act as a tumor suppressor with
proapoptotic and antiproliferative properties. Further-
more, loss of ERβ in ovarian epithelial cells has been
linked to tumorigenesis and has been shown to increase
proliferation of ovarian cancer cells [6, 28]. A clear up-
regulation in the level of ERβ was noted in WFDC2-
knockdown cells, which could partially explain why
high-dose estrogen caused more apoptosis in those cells.
Thus, we hypothesize that upregulation of ERβ caused
by suppression of WFDC2 is part of the mechanism
underlying the decreased growth of these cells.
Because of these results, we further studied the correl-
ation between WFDC2 and a series of genes that were
related to cell proliferation and apoptosis using an apop-
tosis antibody array. In estrogen-sensitive HO8910 cells,
insulin-like growth factor-1 (IGF-1) and insulin-like
growth factor binding protein-1 and 2 (IGFBP-1 and
IGFBP-2), which have been considered to be estrogen-
responsive genes and related to the malignancy and me-
tastasis of ovarian cancer [29–31], were downregulated
in WFDC2-knockdown cells in the protein array.
WFDC2 knockdown has also been shown to decrease
HSP27 expression, which has also been identified as an
estrogen-binding protein, playing a complex role in cell
proliferation, migration and differentiation of estrogen-
responsive tumors [32, 33]. X-linked inhibitor of apop-
tosis protein (XIAP) and survivin, apoptotic suppressors
[34–36], were also found to be downregulated in
WFDC2-knockdown cells. These results are consistent
with our previous hypothesis and explain the role of
WFDC2 in estrogen-dependent cell proliferation and
apoptosis induced by estrogen in ovarian cancer cells.
However, not all the results were in line with our expec-
tations. We expected, that the expression of tumor sup-
pressor genes P21 [37] and HTRA [38, 39] should be
increased by WFDC2 knockdown. But in fact, expression
of these two genes in WFDC2-209 cells was significantly
downregulated.
The results we observed in SKOV3 cells were also not
entirely consistent with what we observed in the
HO8910 cells. There was no evidence to confirm the re-
lationship between WFDC2 and the insulin-like growth
factor pathway, and we did not observe any change in
IGFBP-A, IGF-1, HSP27 or XIAP in SKOV3 cells, al-
though the data were of interest. It is well known that
Bcl-2 family proteins are key regulators of apoptosis [40,
41], in particular, where involvement of the mitochon-
drial apoptotic pathway is concerned. In estrogen-
insensitive SKOV3 cells, proapoptotic genes belonging
to the Bcl2 family, such as Bad, Bax, and Bim were up-
regulated by WFDC2 knockdown. These data led us to
suppose that WFDC2 could take part in cell apoptosis
through the mitochondrial apoptotic pathway. Accord-
ingly, proapoptotic genes, Fasl, Hsp60, caspase 3 and
caspase 8 were also upregulated in WFDC2-knockdown
cells, which also revealed the proapoptotic effects of
WFDC2 knockdown. Additionally, the tumor suppressor
gene P21 was downregulated in WFDC2-knockdown
SKOV3-209 cells, and as seen in HO8910-209 cells. The
contradictory results suggest that WFDC2 might be in-
volved in a complex apoptotic net that will need further
study to unravel.
The inconsistent results obtained using SKOV3 and
HO8910 cells suggested that WFDC2 regulated cell
apoptosis through different pathways in estrogen-
sensitive and estrogen-insensitive cells. The focus of our
upcoming research, therefore, will be to gain a better
understanding of the relationship between WFDC2 and
the insulin-like growth factor pathway to ascertain the
role of WFDC2 on the physiological and pathological be-
havior of ovarian cancer. However, it was the downregu-
lation of the tumor suppressor genes P21 and HTRA,
which led us to question the pathophysiological role of
WFDC2 in tumor initiation and progression. Under-
standing the detailed molecular mechanisms of action of
WFDC2 in cell apoptosis induced with high-dose E2 will
require further study.
Conclusion
In summary, understanding how estrogen is involved in
ovarian cancer development and progression is important
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for determining strategies and targets for ovarian cancer
prevention and treatment. For the first time, we, have
identified WFDC2 as an estrogen target gene that might
be involved in estrogen-induced physiological and patho-
logical events. We also proved that WFDC2 affected
tumor growth in the presence of high-dose estrogen
through gene expression regulation, although further work
on the specific mechanism is needed. Additional studies
of WFDC2 could provide significant information as to its
potential pathophysiological actions in ovarian cancer pro-
gression and might lead to novel strategies for tumor
treatment in patients treated with anti-estrogens.
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Western blot analysis of expression of WFDC2 and GAPDH in HO8910
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determined using densitometry and normalized to GAPDH. *P < 0.05
compared with HO8910-NA; (DOC 293 kb)
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